Manufacturer’s communication to healthcare professionals that nicorandil should not be used as first line treatment for angina -

Manufacturer’s communication to healthcare professionals that nicorandil should not be used as first line treatment for angina
Information type: Safety alerts
Source: Sanofi UK
Specialities: Cardiovascular system disorders | Eyes and vision | Gastrointestinal disorders
Summary
The manufacturers have highlighted that nicorandil is only recommended in patients who have not responded adequately to first line anti-anginals as it can cause serious skin and mucosal ulceration which persists until treatment is discontinued.
UKMi comment
The MHRA produced information in a Drug Safety Update in 2008 with regards to risk of gastro-intestinal ulceration with nicorandil.
Related links: MHRA Drug Safety Alert